Prometheus and Longboard make the leap to Nasdaq with 9-figure offerings and are joined by a Falcon Edge-backed SPAC
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
It’s been hard to match the whirlwind first two months of the year in terms of IPO momentum, and March so far has been relatively quiet on that front. But that doesn’t mean companies aren’t taking the leap — now, two more biotechs and a SPAC are hopping aboard the train.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.